Khan Shabih, MD
Nephrology · Charleston, WVNPI 1285720524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,303 and has fallen 80.7% since, to $251 in 2025.
Across 282 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$1K
- Otsuka America Pharmaceutical, Inc.$980
- Vifor Pharma, Inc.$800
- Mallinckrodt Hospital Products Inc.$283
- Novo Nordisk$274
- plus $1K from 13 others
What the payments were for
- Food & beverage$5,927100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 68 | $1,169 |
| Amgen(2 entities) | 40 | $1,048 |
| Otsuka America Pharmaceutical, Inc. | 51 | $980 |
| Vifor Pharma, Inc. | 42 | $800 |
| Mallinckrodt Hospital Products Inc. | 11 | $283 |
| Novo Nordisk | 3 | $274 |
| Novartis | 11 | $229 |
| Arbor Pharmaceuticals, Inc. | 13 | $217 |
| GSK | 10 | $208 |
| Bayer | 10 | $187 |
| Aurinia Pharma U.S., Inc. | 7 | $173 |
| Travere Therapeutics, Inc. | 4 | $86 |
| OPKO Pharmaceuticals, LLC | 4 | $75 |
| Nxstage Medical, Inc. | 1 | $72 |
| Calliditas Therapeutics US Inc. | 3 | $58 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,947 in reported general payments places this provider in the 85th percentile of 55 nephrology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 31 | $6,782 |
| Calcitriol | 13 | $175 |
| Losartan Potassium | 16 | $111 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Charleston
- Asif RahmanCharleston$8K
- Faroug SulimanCharleston$6K
- Manzar HussainCharleston$4K
- Mary Lou LewisCharleston$48
- Sakshi VaishnavCharleston$0
- Julian EspirituSouth Charleston$215K
- Abdul ZanabliS Charleston$31K
- Murad KheetanHuntington$25K
- Arijit ChakravartyMorgantown$19K
- Mirza HamiraniVienna$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.